Revelation Biosciences (REVB) Q4 2025 earnings summary

Executive summary

• Positive results announced from PRIME clinical study in late-stage chronic kidney disease patients.

• Agreement reached with FDA for a single adaptive Phase 2/3 study for Gemini in acute kidney injury.

• Clinical data on Gemini to be presented at a major nephrology conference in early 2026.

Financial highlights

• Cash and cash equivalents were $10.7 million as of December 31, 2025, up from $6.5 million a year earlier.

• Net cash used for operating activities was $8.3 million for 2025, down from $18.3 million in 2024.

• Net loss for Q4 2025 was $2.5 million ($1.65 per share), compared to $1.7 million ($59.76 per share) in Q4 2024.

• Net loss for the year was $8.9 million ($23.95 per share), improved from $15.0 million ($1,052.16 per share) in 2024.

• Received $6.7 million in net proceeds from warrant inducement in January 2026.

Outlook and guidance

• Current cash and cash equivalents expected to fund operations into Q1 2027.

• Focus remains on advancing Gemini through clinical development and regulatory approval.